Medtronic wins FDA approval for Simplera CGM

Medtronic at Canada Headquarters in Brampton, Ontario, Canada.

JHVEPhoto/iStock Editorial via Getty Images

Medtronic’s (NYSE:MDT) Simplera continuous glucose monitor (CGM) has received regulatory approval from the U.S. Food and Drug Administration (FDA).

Simplera is the company’s first disposable, all-in-one continuous glucose monitor that is half the size of its previous CGMs.

The Medtronic

Leave a Reply

Your email address will not be published. Required fields are marked *